MannKind | MNKD - Operating Profit

Stock Price
3.72
Daily Change
-1.83 -32.94%
Monthly
-33.42%
Yearly
-32.08%
Q1 Forecast
5.37

MannKind reported $-41.05M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Adma Biologics USD 51.01M 8.21M Sep/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
Eli Lilly USD 8.99B 599.9M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
MacroGenics USD 18.64M 55.4M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Merck USD 6.24B 318M Dec/2025
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD -134.02M 296.12M Sep/2024
Novo Nordisk DKK 5.18B 33.61B Jun/2025
Pfizer USD 4.65B 3.99B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Xencor USD -47.52M 14.35M Sep/2025